This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, Y. Articles by Kohno, S. Search for Related Content PubMed PubMed Citation Articles by Nakamura, Y. Articles by Kohno, S.

Gefitinib ("Iressa", ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug Resistance

¹ Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan; ² Division of Respiratory Medicine, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan; and ³ Department of Drug Metabolism and Disposition, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan

Requests for reprints: Mikio Oka, Division of Respiratory Medicine, Department of Internal Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan. Phone: 81-86-462-1111; Fax: 81-86-464-1041; E-mail: moom{at}med.kawasaki-m.ac.jp.

Gefitinib ("Iressa", ZD1839) is an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, and the single agent is clinically effective in non–small cell lung cancer. Although gefitinib combined with various cytotoxic agents has been reported to enhance cytotoxicity in vitro and in mouse models, the mechanism remains undetermined. Here, to explore the mechanism with topoisomerase I inhibitors, we focused on the efflux pump of the breast cancer resistance protein (BCRP/ABCG2), and then examined whether gefitinib restored drug sensitivity in multidrug-resistant cancer cells overexpressing BCRP. We used PC-6 human small cell lung cancer cells and multidrug-resistant PC-6/SN2-5H cells selected with SN-38 of the active metabolite of irinotecan, and BCRP-overexpressing MCF-7/MX cells selected with mitoxantrone and BCRP cDNA transfectant MCF-7/clone 8 cells. Drug sensitivity against anticancer drugs was determined by tetrazolium dye assay, and intracellular topotecan accumulation by FACScan. The topotecan transport study was done using the plasma membrane vesicles of PC-6/SN2-5H cells. The resistant PC-6/SN2-5H cells overexpressed BCRP but not epidermal growth factor receptor mRNA. Ten micromoles of gefitinib reversed topotecan, SN-38, and mitoxantrone resistance, and increased the intracellular topotecan accumulation in the resistant cells but not in the parental cells. Furthermore, gefitinib inhibited the topotecan transport into the vesicles, and the K_i value was 1.01 ± 0.09 µmol/L in the Dixon plot analysis, indicating direct inhibition of BCRP by gefitinib. However, gefitinib was not transported into the vesicles with the high-performance liquid chromatography method. These results indicate that gefitinib reverses BCRP-mediated drug resistance by direct inhibition other than competitive inhibition as a BCRP substrate. Combination of gefitinib and topoisomerase I inhibitors could be clinically effective in cancers expressing BCRP.

Key Words: EGFR inhibitor • Drug resistance • ABC transporter • Topoisomerase I inhibitor • Lung cancer

This article has been cited by other articles:

				J. R. Molina, S. H. Kaufmann, J. M. Reid, S. D. Rubin, M. Galvez-Peralta, R. Friedman, K. S. Flatten, K. M. Koch, T. M. Gilmer, R. J. Mullin, et al. Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data Clin. Cancer Res., December 1, 2008; 14(23): 7900 - 7908. [Abstract] [Full Text] [PDF]

				A. Zannetti, F. Iommelli, R. Fonti, A. Papaccioli, J. Sommella, A. Lettieri, G. Pirozzi, R. Bianco, G. Tortora, M. Salvatore, et al. Gefitinib Induction of In vivo Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Trisphosphate Receptor Type 3 Clin. Cancer Res., August 15, 2008; 14(16): 5209 - 5219. [Abstract] [Full Text] [PDF]

				S. Marchetti, N. A. de Vries, T. Buckle, M. J. Bolijn, M. A.J. van Eijndhoven, J. H. Beijnen, R. Mazzanti, O. van Tellingen, and J. H.M. Schellens Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice Mol. Cancer Ther., August 1, 2008; 7(8): 2280 - 2287. [Abstract] [Full Text] [PDF]

				C. M. Rudin, W. Liu, A. Desai, T. Karrison, X. Jiang, L. Janisch, S. Das, J. Ramirez, B. Poonkuzhali, E. Schuetz, et al. Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity J. Clin. Oncol., March 1, 2008; 26(7): 1119 - 1127. [Abstract] [Full Text] [PDF]

				Z. Shi, X.-X. Peng, I.-W. Kim, S. Shukla, Q.-S. Si, R. W. Robey, S. E. Bates, T. Shen, C. R. Ashby Jr., L.-W. Fu, et al. Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2 Mediated Drug Resistance Cancer Res., November 15, 2007; 67(22): 11012 - 11020. [Abstract] [Full Text] [PDF]

				C. Kersting, C. Gebert, K. Agelopoulos, H. Schmidt, P. J. van Diest, H. Juergens, W. Winkelmann, M. Kevric, G. Gosheger, B. Brandt, et al. Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome Clin. Cancer Res., May 15, 2007; 13(10): 2998 - 3005. [Abstract] [Full Text] [PDF]

				W. Liu, M. R. Baer, M. J. Bowman, P. Pera, X. Zheng, J. Morgan, R. A. Pandey, and A. R. Oseroff The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2 Clin. Cancer Res., April 15, 2007; 13(8): 2463 - 2470. [Abstract] [Full Text] [PDF]

				I Chau, D Cunningham, T Hickish, A Massey, L Higgins, R Osborne, N Botwood, and A Swaisland Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study Ann. Onc., April 1, 2007; 18(4): 730 - 737. [Abstract] [Full Text] [PDF]

				G. Cusatis, V. Gregorc, J. Li, A. Spreafico, R. G. Ingersoll, J. Verweij, V. Ludovini, E. Villa, M. Hidalgo, A. Sparreboom, et al. Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib J Natl Cancer Inst, December 6, 2006; 98(23): 1739 - 1742. [Abstract] [Full Text] [PDF]

				Y. Zhuang, C. H. Fraga, K. E. Hubbard, N. Hagedorn, J. C. Panetta, C. M. Waters, and C. F. Stewart Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor Cancer Res., December 1, 2006; 66(23): 11305 - 11313. [Abstract] [Full Text] [PDF]

				E. E.W. Cohen Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., June 10, 2006; 24(17): 2659 - 2665. [Abstract] [Full Text] [PDF]

				H. E. M. zu Schwabedissen, M. Grube, A. Dreisbach, G. Jedlitschky, K. Meissner, K. Linnemann, C. Fusch, C. A. Ritter, U. Volker, and H. K. Kroemer EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP) Drug Metab. Dispos., April 1, 2006; 34(4): 524 - 533. [Abstract] [Full Text] [PDF]

				C. Xue, J. Wyckoff, F. Liang, M. Sidani, S. Violini, K.-L. Tsai, Z.-Y. Zhang, E. Sahai, J. Condeelis, and J. E. Segall Epidermal Growth Factor Receptor Overexpression Results in Increased Tumor Cell Motility In vivo Coordinately with Enhanced Intravasation and Metastasis Cancer Res., January 1, 2006; 66(1): 192 - 197. [Abstract] [Full Text] [PDF]

				G. Gasparini, R. Sarmiento, S. Amici, R. Longo, D. Gattuso, M. Zancan, and M. Gion Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate Ann. Onc., December 1, 2005; 16(12): 1867 - 1873. [Abstract] [Full Text] [PDF]